Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).

[1]  L. Cavanna,et al.  Dexamethasone‐Sparing Regimens with Oral Netupitant and Palonosetron for the Prevention of Emesis Caused by High‐Dose Cisplatin: A Randomized Noninferiority Study , 2021, The oncologist.

[2]  H. Arioka,et al.  Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy , 2020, BMJ Open.

[3]  T. Nishidate,et al.  Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: Update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis , 2020, International Journal of Clinical Oncology.

[4]  Geoffrey Liu,et al.  Reducing dexamethasone antiemetic prophylaxis during the COVID-19 pandemic: recommendations from Ontario, Canada , 2020, Supportive Care in Cancer.

[5]  Qiurong Ruan,et al.  Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China , 2020, Intensive Care Medicine.

[6]  W. Yeo,et al.  A randomized study of olanzapine-containing versus standard antiemetic regimens for the prevention of chemotherapy-induced nausea and vomiting in Chinese breast cancer patients , 2020, Breast.

[7]  M. Aapro,et al.  Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence , 2019, BMC Cancer.

[8]  K. Jerzak,et al.  ASCO, NCCN, MASCC/ESMO: a comparison of antiemetic guidelines for the treatment of chemotherapy-induced nausea and vomiting in adult patients , 2018, Supportive Care in Cancer.

[9]  H. Hashimoto,et al.  A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy , 2018, International Journal of Clinical Oncology.

[10]  M. Tsuboi,et al.  Japanese translation and linguistic validation of the US National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) , 2017, Journal of Patient-Reported Outcomes.

[11]  H. Kenmotsu,et al.  A Phase II study of palonosetron, aprepitant, dexamethasone and olanzapine for the prevention of cisplatin-based chemotherapy-induced nausea and vomiting in patients with thoracic malignancy , 2017, Japanese journal of clinical oncology.

[12]  A. Molassiotis,et al.  The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  S. Nishikawa,et al.  A Prospective Observational Study on Effect of Short‐Term Periodic Steroid Premedication on Bone Metabolism in Gastrointestinal Cancer (ESPRESSO‐01) , 2017, The Oncologist.

[14]  M. Cecchini,et al.  Ultrastructural Characterization of the Lower Motor System in a Mouse Model of Krabbe Disease , 2016, Scientific Reports.

[15]  Ali Bijani,et al.  Efficacy of olanzapine in symptom relief and quality of life in gastric cancer patients receiving chemotherapy , 2016, Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences.

[16]  I. Petersen,et al.  Common Infections in Patients Prescribed Systemic Glucocorticoids in Primary Care: A Population-Based Cohort Study , 2016, PLoS medicine.

[17]  K. Lee,et al.  A Pilot Study Evaluating Steroid-Induced Diabetes after Antiemetic Dexamethasone Therapy in Chemotherapy-Treated Cancer Patients , 2016, Cancer research and treatment : official journal of Korean Cancer Association.

[18]  R. Navari,et al.  Olanzapine versus aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a randomized phase III trial. , 2011, The journal of supportive oncology.

[19]  S. Grunberg.  Antiemetic activity of corticosteroids in patients receiving cancer chemotherapy: dosing, efficacy, and tolerability analysis. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  Kimberly S. Chiew,et al.  Side effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy , 2005, British Journal of Cancer.

[21]  A. Stuck,et al.  Risk of infectious complications in patients taking glucocorticosteroids. , 1989, Reviews of infectious diseases.